LAB vs. QTRX, EYPT, CTKB, PACB, ADPT, NAUT, AKYA, TMCI, HLVX, and BCYC
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Cytek Biosciences (CTKB), Pacific Biosciences of California (PACB), Adaptive Biotechnologies (ADPT), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Treace Medical Concepts (TMCI), HilleVax (HLVX), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.
Quanterix received 264 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
In the previous week, Quanterix had 16 more articles in the media than Standard BioTools. MarketBeat recorded 18 mentions for Quanterix and 2 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.07 beat Quanterix's score of -0.19 indicating that Quanterix is being referred to more favorably in the media.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 6.9% of Quanterix shares are owned by company insiders. Comparatively, 53.1% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Quanterix has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -70.98%. Standard BioTools' return on equity of -10.39% beat Quanterix's return on equity.
Quanterix has higher revenue and earnings than Standard BioTools. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Quanterix currently has a consensus price target of $30.60, suggesting a potential upside of 72.10%. Standard BioTools has a consensus price target of $3.58, suggesting a potential upside of 41.63%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Quanterix is more favorable than Standard BioTools.
Summary
Quanterix beats Standard BioTools on 14 of the 19 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
